Wanxiang Healthcare Investments (WHI) is the corporate venture capital arm of Wanxiang America, the US subsidiary of Wanxiang Group Corporation. It invests in early to growth-stage healthcare technology companies, with an emphasis on digital health, medical devices, and biotechnology.
80% of their portfolio is in Healthcare. Their most common stage is series-a (40% of deals). Average disclosed round size is $20.9M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Carallel | Series A | $8.2M | Jan 2022 |
 Augmedix | Series B | $19M | Oct 2019 |
 Endotronix | Series D | $45M | Sep 2018 |
 OM1 | Series C | $50M | May 2018 |
| CConsejoSano | Series A | $4.9M | Feb 2017 |
 Exo Imaging | Growth | — | — |
 Watershed Health | Unknown | $13.6M | — |
 QbD Vision | Series A | $13M | — |
| OM1 | Series A | $15M | — |
 Augmedix | Series B | $19M | — |
Top Co-Investors
7wire Ventures3 shared
Scale Venture Partners2 shared
Impact Engine2 shared
FCA Venture Partners2 shared
General Catalyst2 shared
Redmile Group2 shared
McKesson Ventures2 shared
DCM Ventures2 shared
EQT Life Sciences1 shared
Illumina Ventures1 shared
SJF Ventures1 shared
Blu Ventures1 shared
Aperture Venture Partners1 shared
SV Health Investors1 shared
Wanxiang Group Corporation1 shared
Seroba Life Sciences1 shared
Action Potential Venture Capital1 shared
AJU IB Investment1 shared
Creative Ventures1 shared
Solasta Ventures1 shared
Last updated: 20 October 2026